In a groundbreaking pilot study, researchers have introduced an innovative approach to deep brain stimulation (DBS) that may greatly enhance the lives of individuals with Parkinson’s disease. This technique, referred
Pharmaceutical13- Page
202Articles
In a world where numerous industries are reevaluating the transformative potential of artificial intelligence (AI), the pharmaceutical sector is already experiencing revolutionary changes in drug discovery. Companies like GSK and
The fate of AstraZeneca’s planned £450 million investment in a vaccine manufacturing facility in northwest England hangs in the balance as the Treasury, under the leadership of Chancellor Rachel Reeves,
The National Health Service (NHS) has announced a groundbreaking initiative to tackle the growing threat of antimicrobial resistance (AMR) by partnering with the pharmaceutical industry. The NHS will negotiate fixed-fee
A pharmaceutical giant will test an experimental treatment in response to the surge in demand for obesity treatments Pfizer has accelerated the trials of a weight loss pill that can
Arecor Therapeutics PLC, listed on AIM as AREC, has been making waves in the healthcare industry with its innovative approach to diabetes and obesity treatments. In a recent interview with
After Emmanuel Macron’s charm offensive, the two largest pharmaceutical companies in Britain have committed £430m to France. AstraZeneca, GSK and other pharmaceutical companies have pledged to upgrade their facilities within
Imaging Biometrics, a subsidiary of IQ-AI Ltd, has recently made a significant announcement regarding its lead drug candidate, IB-003. The US Food and Drug Administration (FDA) has granted Rare Pediatric
Shield Therapeutics, a pharmaceutical company focusing on iron deficiency treatments, has reported a significant increase in revenues for the year 2023. The company’s sales of its Accrufer/Feraccru iron deficiency treatment
Sir John Bell, one of Britain’s leading life sciences leaders, warned of an imminent exodus of pharmaceutical companies from London, calling the City “a bad place to raise funds”. Sir
